SlideShare a Scribd company logo
1 of 19
FDA Overview 
 Regulates about 25% of all consumer 
purchases 
 Mission summary: protect and advance public 
health 
 Products: food, cosmetics, drugs, biologics, 
medical devices 
 Pre-market and post-market responsibilities 
and operations 
 About 10,000 employees operating in product 
Centers, OC, and ORA
What is a Recall? 
Recall – a firm’s removal or correction of 
a marketed product that is in violation of 
the law, and against which FDA would 
initiate legal action. 
Reference: 21 CFR 7.3(g)
& Analysis Other Health Agencies 
FDA inspection 
FDA Sample Collection 
Firm Testing 
How Does FDA Learn About a 
Problem with a Regulated Product? 
NDA Field 
Reports 
CDC 
Epidemiological 
Information 
Adverse Event 
Reports 3rd party information
What Does a Firm Do When a Problem 
is Detected in a Marketed Product? 
 Review, analyze, discuss, debate 
 Often get to the decision point: ‘remove 
the product from the market’ 
 Then: scope, strategy, notification, 
execution, verification, and analysis
Steps Taken By a Firm When 
Conducting a Recall 
 Scope – the specific products to recall 
 Strategy – the plan to execute the 
removal or correction to minimize risk of 
illness/injury from recalled product 
 Notification – inform FDA* of the 
planned recall; offering the opportunity 
to comment on the scope and strategy.
Steps Taken By a Firm When 
Conducting a Recall (cont’d) 
 Execution - make the recall happen; calls, 
emails, faxes, letters, visits, internet 
posting, press releases 
 Verification - ensure execution of the 
strategy was performed effectively 
 Analysis - review overall effort and identify 
opportunities for improvement
Steps Taken By FDA in the Recall 
Process 
 Assess situation & obtain recall related 
information (e.g. labeling, distribution, testing) 
 Investigate - What went wrong? What steps 
were taken to prevent recurrence? 
 Evaluate scope and strategy - Is it appropriate 
in light of the risk? Adjustments needed? 
Other steps needed? Additional public notice 
necessary?
Steps Taken By FDA in the 
Recall Process (cont’d) 
 Health hazard evaluation and classification 
of the recall; publication in the Enforcement 
Report 
 Recall audit checks; level is set based on 
risk to verify the effectiveness of the recall 
efforts
How is a Recall Classified? 
 Class 1 - highest risk; reasonable probability of 
serious adverse health consequences or death 
 Class 2 - medium risk; may cause temporary or 
medically reversible adverse health 
consequences and probability of serious adverse 
health consequences is remote 
 Class 3 – low risk; adverse health consequences 
are unlikely 
Classification is a legal determination based on the 
health hazard evaluation. FDA oversight is 
commensurate with risk and therefore 
proportional to classification 
Reference: 21 CFR 7.3(m)
When is a Recall Classified? 
 Upon receipt and review of all pertinent 
information relevant to the recall 
 After an assessment of the health hazard 
associated with the recalled product has 
been made 
 As soon as reasonably possible
What Are the Practical Implications 
of a Recall Classification? 
Class 1 & 2 Recalls May Require Additional 
Actions Be Undertaken: 
–Option for FDA to issue a public warning 
per 21 CFR 7.42(b)(2) 
–Guidance to Industry recommends 
procedures for issuing Public Notifications 
(Press Releases) in certain situations
Public Communication 
Class 1 Recall: 
– Prompt, clear, accurate communication 
reduces the risk of serious injury or death 
– Press Releases are usually issued to 
enhance the consumer’s awareness of the 
recall and the steps that should be taken
Public Communication (cont’d) 
Class 1 Recall: 
– Press releases also post to the FDA internet 
site and are sent to all state health agencies, 
foreign governments, and various other 
stakeholders 
– There are several hundred Class 1 recalls 
per year across all FDA regulated products 
– Look how The Washington Post now 
presents product recall notices…
Daily Washington Post Notices
Daily Washington Post Notices
Daily Washington Post Notices
Daily Washington Post Notices
Legislation and New Initiatives 
 FDAAA Section 1003 
– Enhance the quality and speed of 
communication with the public 
– Post information that is easily accessed and 
understood by the public 
 Food Protection Plan 
– Improve the food protection communication 
process to increase timeliness of food 
protection messages 
– Better inform consumers and other 
stakeholders during food related emergencies
Legislation and New Initiatives (cont’d) 
 Import Safety Action Plan 
– Provide FDA with mandatory food recall 
authority 
–Develop best practices for the use of 
technologies to expedite consumer 
notification of recalls

More Related Content

What's hot

Pharmacovigilance full information
Pharmacovigilance full informationPharmacovigilance full information
Pharmacovigilance full information
Ravindra Kumar
 
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Bhaswat Chakraborty
 
Brenda Driscoll Resume 3-4-16
Brenda Driscoll Resume 3-4-16Brenda Driscoll Resume 3-4-16
Brenda Driscoll Resume 3-4-16
Brenda Driscoll
 

What's hot (20)

Beyond Scaling Up: Prequalification of Medicines
Beyond Scaling Up: Prequalification of Medicines Beyond Scaling Up: Prequalification of Medicines
Beyond Scaling Up: Prequalification of Medicines
 
Presentation: CMA Advertising Seminar
Presentation: CMA Advertising SeminarPresentation: CMA Advertising Seminar
Presentation: CMA Advertising Seminar
 
Risk Management In Pharmacovigilance
Risk Management In PharmacovigilanceRisk Management In Pharmacovigilance
Risk Management In Pharmacovigilance
 
Pharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirementsPharmacovigilance and complementary medicines - Regulatory requirements
Pharmacovigilance and complementary medicines - Regulatory requirements
 
Professor Peivand Pirouzi Inc. - Pharmacovigilance Inspections: Representati...
Professor Peivand Pirouzi Inc. - Pharmacovigilance Inspections: Representati...Professor Peivand Pirouzi Inc. - Pharmacovigilance Inspections: Representati...
Professor Peivand Pirouzi Inc. - Pharmacovigilance Inspections: Representati...
 
Pharmacovigilance forum
Pharmacovigilance forumPharmacovigilance forum
Pharmacovigilance forum
 
Lessons for Tropical Disease drug development
 Lessons for Tropical Disease drug development Lessons for Tropical Disease drug development
Lessons for Tropical Disease drug development
 
Pharmacovigilance Basics for fresher's as well as experience candidates
Pharmacovigilance Basics for fresher's as well as experience candidatesPharmacovigilance Basics for fresher's as well as experience candidates
Pharmacovigilance Basics for fresher's as well as experience candidates
 
Fda guidance for pharmaceutical post marketing reporting professor pirouzi
Fda guidance for pharmaceutical post marketing reporting   professor pirouziFda guidance for pharmaceutical post marketing reporting   professor pirouzi
Fda guidance for pharmaceutical post marketing reporting professor pirouzi
 
Pharmacovigilance full information
Pharmacovigilance full informationPharmacovigilance full information
Pharmacovigilance full information
 
Cliniminds- Skill Development Program in Pharmacovigilance
Cliniminds- Skill Development Program in PharmacovigilanceCliniminds- Skill Development Program in Pharmacovigilance
Cliniminds- Skill Development Program in Pharmacovigilance
 
Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
Presentation: Therapeutic Goods Advertising Code (No. 2) 2018Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
 
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
 
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...
 
RECALL PROCEDURES // FOOD SAFETY
RECALL PROCEDURES // FOOD SAFETYRECALL PROCEDURES // FOOD SAFETY
RECALL PROCEDURES // FOOD SAFETY
 
Common arab guidelines in pharmacovigilance
Common arab guidelines in pharmacovigilanceCommon arab guidelines in pharmacovigilance
Common arab guidelines in pharmacovigilance
 
CER - PMS - PMCF
CER - PMS - PMCFCER - PMS - PMCF
CER - PMS - PMCF
 
Guideline on good pharmacovigilance practices ( gvp)
Guideline on good pharmacovigilance practices ( gvp)Guideline on good pharmacovigilance practices ( gvp)
Guideline on good pharmacovigilance practices ( gvp)
 
Brenda Driscoll Resume 3-4-16
Brenda Driscoll Resume 3-4-16Brenda Driscoll Resume 3-4-16
Brenda Driscoll Resume 3-4-16
 
Annexure 1 pharmacovigilance
Annexure 1  pharmacovigilanceAnnexure 1  pharmacovigilance
Annexure 1 pharmacovigilance
 

Similar to Fd arecall

post marketing surveillance OF DRUG PRODUCTS
post marketing surveillance OF DRUG PRODUCTSpost marketing surveillance OF DRUG PRODUCTS
post marketing surveillance OF DRUG PRODUCTS
PrakashGoudanavar
 
METHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCEMETHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCE
Dr Arathy R Nath
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
bdvfgbdhg
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
bdvfgbdhg
 
HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015
HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015  HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015
HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015
Tomas J. Philipson
 
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-1...
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-1...FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-1...
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-1...
Takuji Shimomura
 

Similar to Fd arecall (20)

Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
Recalls: The First Smoke of A Mass Tort -- Overview of a Recall of an FDA-Reg...
 
post marketing surveillance OF DRUG PRODUCTS
post marketing surveillance OF DRUG PRODUCTSpost marketing surveillance OF DRUG PRODUCTS
post marketing surveillance OF DRUG PRODUCTS
 
FDA Enforcement: The Cop is Back – How Enhanced Enforcement Can Impact You a...
FDA Enforcement:  The Cop is Back – How Enhanced Enforcement Can Impact You a...FDA Enforcement:  The Cop is Back – How Enhanced Enforcement Can Impact You a...
FDA Enforcement: The Cop is Back – How Enhanced Enforcement Can Impact You a...
 
METHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCEMETHODS OF POST MARKETING SURVEILLANCE
METHODS OF POST MARKETING SURVEILLANCE
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
 
Patient safety
Patient safetyPatient safety
Patient safety
 
HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015
HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015  HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015
HEDGING PIPELINE RISK IN PHARMA FDA Swaps and Annuities 3.2015
 
Postmarket Surveillance Medical Devices
Postmarket Surveillance   Medical DevicesPostmarket Surveillance   Medical Devices
Postmarket Surveillance Medical Devices
 
Clinical research : Drug regulatory affairs and Pharmacovigilance.
Clinical research : Drug regulatory affairs and Pharmacovigilance.Clinical research : Drug regulatory affairs and Pharmacovigilance.
Clinical research : Drug regulatory affairs and Pharmacovigilance.
 
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate ComplianceFDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
 
Food Recall Readiness - Is Your Plan In Place?
Food Recall Readiness - Is Your Plan In Place?Food Recall Readiness - Is Your Plan In Place?
Food Recall Readiness - Is Your Plan In Place?
 
FDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate ComplianceFDA Enforcement -- the Perils of Inadequate Compliance
FDA Enforcement -- the Perils of Inadequate Compliance
 
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-1...
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-1...FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-1...
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-1...
 
FDA Guidance on Conduct of Clinical Trials of Medical Products during Covid-1...
FDA Guidance on Conduct of Clinical Trials of Medical Products during Covid-1...FDA Guidance on Conduct of Clinical Trials of Medical Products during Covid-1...
FDA Guidance on Conduct of Clinical Trials of Medical Products during Covid-1...
 
Health Canada New Naming Guidance June, 2015
Health Canada New Naming Guidance June, 2015Health Canada New Naming Guidance June, 2015
Health Canada New Naming Guidance June, 2015
 
Health Canada Brand Name Guidance Document. July, 2015
Health Canada Brand Name Guidance Document.  July, 2015Health Canada Brand Name Guidance Document.  July, 2015
Health Canada Brand Name Guidance Document. July, 2015
 
Drug Safety – Perspectives on Industry’s Duties in the Post-Vioxx Age
Drug Safety – Perspectives on Industry’s Duties in the Post-Vioxx AgeDrug Safety – Perspectives on Industry’s Duties in the Post-Vioxx Age
Drug Safety – Perspectives on Industry’s Duties in the Post-Vioxx Age
 
3..Post marketing surveillance.pptx
3..Post marketing surveillance.pptx3..Post marketing surveillance.pptx
3..Post marketing surveillance.pptx
 
Overview of FDA requirements for IND
Overview of FDA requirements for INDOverview of FDA requirements for IND
Overview of FDA requirements for IND
 

More from cqpate (20)

STD
STDSTD
STD
 
Urinary noyouranary 2
Urinary noyouranary 2Urinary noyouranary 2
Urinary noyouranary 2
 
Corticosteroids
CorticosteroidsCorticosteroids
Corticosteroids
 
Antihistamines, antitussives, decongestants, expectorants
Antihistamines, antitussives, decongestants, expectorantsAntihistamines, antitussives, decongestants, expectorants
Antihistamines, antitussives, decongestants, expectorants
 
Firstaid
FirstaidFirstaid
Firstaid
 
Sterile enviroment
Sterile enviromentSterile enviroment
Sterile enviroment
 
Rx order
Rx orderRx order
Rx order
 
Retaildelivery
RetaildeliveryRetaildelivery
Retaildelivery
 
Restricteddrugpate
RestricteddrugpateRestricteddrugpate
Restricteddrugpate
 
Regulatgion audit
Regulatgion auditRegulatgion audit
Regulatgion audit
 
Recordkeeping
RecordkeepingRecordkeeping
Recordkeeping
 
Recallsrefund
RecallsrefundRecallsrefund
Recallsrefund
 
Pointof saleinvenrtory
Pointof saleinvenrtoryPointof saleinvenrtory
Pointof saleinvenrtory
 
Effectofmeds
EffectofmedsEffectofmeds
Effectofmeds
 
Hospital drug rx
Hospital drug rxHospital drug rx
Hospital drug rx
 
Hospdelivery
HospdeliveryHospdelivery
Hospdelivery
 
Pharmadmin
PharmadminPharmadmin
Pharmadmin
 
Analgesics
AnalgesicsAnalgesics
Analgesics
 
Respiratorydrugs
RespiratorydrugsRespiratorydrugs
Respiratorydrugs
 
Hyperlipidemia
HyperlipidemiaHyperlipidemia
Hyperlipidemia
 

Recently uploaded

The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
heathfieldcps1
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
PECB
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
kauryashika82
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
Chris Hunter
 

Recently uploaded (20)

Role Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptxRole Of Transgenic Animal In Target Validation-1.pptx
Role Of Transgenic Animal In Target Validation-1.pptx
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural ResourcesEnergy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701ComPTIA Overview | Comptia Security+ Book SY0-701
ComPTIA Overview | Comptia Security+ Book SY0-701
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 

Fd arecall

  • 1. FDA Overview  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs, biologics, medical devices  Pre-market and post-market responsibilities and operations  About 10,000 employees operating in product Centers, OC, and ORA
  • 2. What is a Recall? Recall – a firm’s removal or correction of a marketed product that is in violation of the law, and against which FDA would initiate legal action. Reference: 21 CFR 7.3(g)
  • 3. & Analysis Other Health Agencies FDA inspection FDA Sample Collection Firm Testing How Does FDA Learn About a Problem with a Regulated Product? NDA Field Reports CDC Epidemiological Information Adverse Event Reports 3rd party information
  • 4. What Does a Firm Do When a Problem is Detected in a Marketed Product?  Review, analyze, discuss, debate  Often get to the decision point: ‘remove the product from the market’  Then: scope, strategy, notification, execution, verification, and analysis
  • 5. Steps Taken By a Firm When Conducting a Recall  Scope – the specific products to recall  Strategy – the plan to execute the removal or correction to minimize risk of illness/injury from recalled product  Notification – inform FDA* of the planned recall; offering the opportunity to comment on the scope and strategy.
  • 6. Steps Taken By a Firm When Conducting a Recall (cont’d)  Execution - make the recall happen; calls, emails, faxes, letters, visits, internet posting, press releases  Verification - ensure execution of the strategy was performed effectively  Analysis - review overall effort and identify opportunities for improvement
  • 7. Steps Taken By FDA in the Recall Process  Assess situation & obtain recall related information (e.g. labeling, distribution, testing)  Investigate - What went wrong? What steps were taken to prevent recurrence?  Evaluate scope and strategy - Is it appropriate in light of the risk? Adjustments needed? Other steps needed? Additional public notice necessary?
  • 8. Steps Taken By FDA in the Recall Process (cont’d)  Health hazard evaluation and classification of the recall; publication in the Enforcement Report  Recall audit checks; level is set based on risk to verify the effectiveness of the recall efforts
  • 9. How is a Recall Classified?  Class 1 - highest risk; reasonable probability of serious adverse health consequences or death  Class 2 - medium risk; may cause temporary or medically reversible adverse health consequences and probability of serious adverse health consequences is remote  Class 3 – low risk; adverse health consequences are unlikely Classification is a legal determination based on the health hazard evaluation. FDA oversight is commensurate with risk and therefore proportional to classification Reference: 21 CFR 7.3(m)
  • 10. When is a Recall Classified?  Upon receipt and review of all pertinent information relevant to the recall  After an assessment of the health hazard associated with the recalled product has been made  As soon as reasonably possible
  • 11. What Are the Practical Implications of a Recall Classification? Class 1 & 2 Recalls May Require Additional Actions Be Undertaken: –Option for FDA to issue a public warning per 21 CFR 7.42(b)(2) –Guidance to Industry recommends procedures for issuing Public Notifications (Press Releases) in certain situations
  • 12. Public Communication Class 1 Recall: – Prompt, clear, accurate communication reduces the risk of serious injury or death – Press Releases are usually issued to enhance the consumer’s awareness of the recall and the steps that should be taken
  • 13. Public Communication (cont’d) Class 1 Recall: – Press releases also post to the FDA internet site and are sent to all state health agencies, foreign governments, and various other stakeholders – There are several hundred Class 1 recalls per year across all FDA regulated products – Look how The Washington Post now presents product recall notices…
  • 18. Legislation and New Initiatives  FDAAA Section 1003 – Enhance the quality and speed of communication with the public – Post information that is easily accessed and understood by the public  Food Protection Plan – Improve the food protection communication process to increase timeliness of food protection messages – Better inform consumers and other stakeholders during food related emergencies
  • 19. Legislation and New Initiatives (cont’d)  Import Safety Action Plan – Provide FDA with mandatory food recall authority –Develop best practices for the use of technologies to expedite consumer notification of recalls

Editor's Notes

  1. Mention that there is essentially no difference in the recall process regardless of whether a firm detects the problem on its own OR if the problem is detected/discovered by FDA. Mention differences between those instances in which a problem is detected in a marketed product vs. problems that are detected during manufacturing or that require reporting per 21 CFR, e.g., Biological Product Deviation Report (BPDR); Notice of Correction & Removal; Adverse Event Report; Medical Device Report; NDA Field Alert.
  2. Per Lee’s suggestion, mention that we are asking the RCAC Members for their help on the recall provisions now, but will be asking them about the consumer behavior studies later. Lee is pretty sure that a number of committee members will be excited about that topic and will want to hear that the Agency will consult them on this topic (similar situation as in the DTC advertising provisions).